Report
Pharmaceuticals KOL meeting on gMG: Advantage to UCB?
A few words about Myasthenia Gravis.What scales to measure the severity of the disease?
Existing treatment algorithm
Anti-C5: likely to be used for chronic treatment
Anti-FcRn: probably more for use in crises
Vyvgart (efgartigimod): the first on the market
Other mechanisms of action: lack of data for a clear statement by our KOL
Conclusion: Anti-C5 for chronic treatment and anti-FcRn for flare-up
Provider
Bryan Garnier
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Jean-Jacques Le Fur
Other Reports from Bryan Garnier
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.